lithium;tetrafluoroborate

• 分子结构分类: 无机化合物 - 混合金属/非金属化合物 - 类金属盐
• 英文名称: lithium;tetrafluoroborate
• 化学式: BF4Li
• 分子量: 93.8
• InChiKey: UFXJWFBILHTTET-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.7
• 重原子数：
  6
• 可旋转键数：
  0
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  0
• 氢给体数：
  0
• 氢受体数：
  5

ADMET

毒理性

• 副作用

Dermatotoxin - 皮肤烧伤。

Dermatotoxin - Skin burns.

来源:Haz-Map, Information on Hazardous Chemicals and Occupational Diseases

反应信息

• 作为反应物：
  描述：

  lithium;tetrafluoroborate 生成 calcium;ditetrafluoroborate
  参考文献：
  名称：

  GREGORY, THOMAS D.

  摘要：

  DOI：
• 作为产物：
  描述：

  三氟化硼 、 氟化锂 生成 lithium;tetrafluoroborate
  参考文献：
  名称：

  MAMANTOV, GLEB

  摘要：

  DOI：

文献信息

• Thrombopoietin mimetics
  申请人：——

  公开号：US20040019190A1

  公开（公告）日：2004-01-29

  Invented are non-peptide TPO mimetics. Also invented are novel processes and intermediates used in the preparation of the presently invented compounds. Also invented is a method of treating thrombocytopenia, in a mammal, including a human, in need thereof which comprises administering to such mammal an effective amount of a selected hydroxy- 1 -azobenzene derivative.

  发明了非肽类TPO类似物。还发明了用于制备现有发明化合物的新型工艺和中间体。还发明了一种治疗血小板减少症的方法，包括对需要该方法的哺乳动物，包括人类，给予所选羟基-1-偶氮苯衍生物的有效量。
• Amino alcohol derivatives, medicinal composition containing the same, and use of these
  申请人：Kobayashi Junichi

  公开号：US20070078184A1

  公开（公告）日：2007-04-05

  The present invention provides compounds represented by general formula (I): a prodrug thereof, or pharmaceutical acceptable salts thereof, wherein R 1 is hydrogen or lower alkyl; each of R2 and R3 is independently hydrogen or lower alkyl; each of R 4 , R 5 and R 6 is independently hydrogen, halogen, lower alkyl or lower alkoxy; R 7 is hydrogen or lower alkyl; R 8 is hydrogen, halogen, lower alkyl, lower alkoxy, etc; R 9 is —COR 10 , -A 1 -COR 10 , —O-A 2 -COR 10 , etc; Ar is optionally substituted phenyl or heteroaryl; and A is a bond, —OCH 2 —, etc, which exhibit potent and selective β3-adrenoceptor stimulating activities. The present invention also provides pharmaceutical compositions containing said compound, and uses thereof.

  本发明提供了由通式（I）表示的化合物：其前体，或其药学上可接受的盐，其中R1是氢或较低的烷基；R2和R3各自独立地是氢或较低的烷基；R4，R5和R6各自独立地是氢，卤素，较低的烷基或较低的烷氧基；R7是氢或较低的烷基；R8是氢，卤素，较低的烷基，较低的烷氧基等；R9是-COR10，-A1-COR10，-O-A2-COR10等；Ar是可选取代的苯基或杂环芳基；A是键，-OCH2-等，这些化合物表现出潜在和选择性的β3-肾上腺素能受体刺激活性。本发明还提供了含有上述化合物的药物组合物及其用途。
• Multi-cyclic cinnamide derivatives
  申请人：Kimura Teiji

  公开号：US20070219181A1

  公开（公告）日：2007-09-20

  The present invention provides a compound represented by the formula (I): or a pharmacologically acceptable salt thereof, wherein Ar 1 represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, Ar 2 represents a phenyl group that may be substituted with a C1-6 alkoxy group, or the like, X 1 represents a double bond or the like, and Het represents an imidazolyl group that may be substituted with a C1-6 alkyl group, or the like, which is effective as a therapeutic or prophylactic agent for a disease caused by Aβ.

  本发明提供了一种化合物，其由公式（I）表示：或其药学上可接受的盐，其中Ar1表示一种咪唑基团，该基团可以被C1-6烷基或类似物取代，Ar2表示一种苯基团，该基团可以被C1-6烷氧基或类似物取代，X1表示双键或类似物，Het表示一种咪唑基团，该基团可以被C1-6烷基或类似物取代，该化合物作为治疗或预防由Aβ引起的疾病的药物有效。
• AZETIDINE AND CYCLOBUTANE DERIVATIVES AS JAK INHIBITORS
  申请人：Rodgers James D.

  公开号：US20090233903A1

  公开（公告）日：2009-09-17

  The present invention relates to azetidine and cyclobutane derivatives, as well as their compositions, methods of use, and processes for preparation, which are JAK inhibitors useful in the treatment of JAK-associated diseases including, for example, inflammatory and autoimmune disorders, as well as cancer.

  本发明涉及吡咯烷和环丁烷衍生物，以及它们的组合物、使用方法和制备方法，这些JAK抑制剂可用于治疗与JAK相关的疾病，例如炎症和自身免疫性疾病，以及癌症。
• Urea Derivative
  申请人：Kurata Hitoshi

  公开号：US20070249620A1

  公开（公告）日：2007-10-25

  The present invention relates to a urea derivative or a pharmacologically acceptable salt thereof having an excellent DGAT inhibitory effect. A urea derivative having the formula: [wherein R 1 is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; R is a C 6 -C 10 aryl group which may be independently mono- to pentasubstituted by a group selected from Substituent Group a or others; E is a group having the formula (II) or the formula (III) (wherein R 3 is a hydrogen atom or others; R 4 and R 5 , which are the same or different, are a hydrogen atom or others; X and U, which are the same or different, are a group represented by the formula CH or others; m and n, which are the same or different, are I or another number) or others; and A is a group represented by the formula —NH—C(═O)— or others], or a pharmacologically acceptable salt thereof.

  本发明涉及一种具有出色DGAT抑制作用的脲衍生物或其药理学上可接受的盐。其中，该脲衍生物具有以下公式：[式中，R1是C6-C10芳基，可以独立地被来自置换基团a或其他的基团单独到五重取代；R是C6-C10芳基，可以独立地被来自置换基团a或其他的基团单独到五重取代；E是具有公式（II）或公式（III）的基团（其中，R3是氢原子或其他；R4和R5相同或不同，是氢原子或其他；X和U相同或不同，是由公式CH或其他表示的基团；m和n相同或不同，是I或其他数字）或其他；A是由公式—NH—C(═O)—或其他表示的基团]，或其药理学上可接受的盐。